Healthcare stocks were leaning lower pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.5% and the iShares Biotechnology ETF (IBB) declining by 1%.
Ultragenyx Pharmaceutical (RARE) has received accelerated approval from the US Food and Drug Administration for Genglycos to treat glycogen storage disease type Ia, a rare genetic metabolic disorder due to an enzyme deficiency, the drugmaker said. Ultragenyx Pharmaceutical shares were up more than 6% premarket.